TriLink BioTechnologies社 October TriLink Messenger
This Zon blog post gives background about the general concepts for mRNA reporter genes, before describing four recent examples of mRNA therapies investigated using off-the-shelf CleanCap mRNA reporters. The examples discussed here demonstrate the utility of mRNA reporters to confirm delivery and translation in various model systems such as airway tissue remodeling in chronic obstructive pulmonary diseases and mRNA replacement therapies for cystic fibrosis.
The development and regulatory approval of chimeric antigen receptor (CAR) T cells targeting the B cell marker CD19 represents a major breakthrough in cancer immunotherapy. However, using a similar approach to treat T cell malignancies is more challenging due to the shared expression of target antigens by therapeutic, normal, and malignant T cells. Read more about how TriLink's sgRNA was used for this research.
CRISPR-Cas base editors have been limited by a lack of tools for designing and ranking the DNA targeting component, single-guide RNA (sgRNA). To address this need, researchers at the University of Minnesota recently developed a modular platform termed SpliceR and used it to compare gene disruption approaches in T cells. Read more about how TriLink's BE4, ABE7.10, and SpCas9 mRNA was used for this research.
Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。